AR096848A1 - Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) - Google Patents

Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)

Info

Publication number
AR096848A1
AR096848A1 ARP140102528A ARP140102528A AR096848A1 AR 096848 A1 AR096848 A1 AR 096848A1 AR P140102528 A ARP140102528 A AR P140102528A AR P140102528 A ARP140102528 A AR P140102528A AR 096848 A1 AR096848 A1 AR 096848A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
independently
hydrogen atom
ring
Prior art date
Application number
ARP140102528A
Other languages
English (en)
Inventor
Aida Jumpei
Takahashi Masashi
Kakegawa Keiko
Ikoma Minoru
Igawa Hideyuki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of AR096848A1 publication Critical patent/AR096848A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proporciona un compuesto que tiene una acción antagonista del receptor de la hormona concentradora de melanina y que es útil como agente para la profilaxis o el tratamiento de la obesidad y similares. Reivindicación 1: Un compuesto representado por la fórmula (1), caracterizado porque el anillo Ar es un anillo aromático además sustituido en forma opcional; L¹ es O, S(O)ₘ₁, NR³A o CR³BR³C; L² es O, S(O)ₘ₂, NR⁴A o CR⁴BR⁴C; (con la exclusión de la combinación en que L¹ sea distinto de CR³BR³C y L² sea distinto de CR⁴BR⁴C); m1 y m2 son cada uno en forma independiente un número entero de 0 a 2; R³A y R⁴A son cada uno en forma independiente un átomo de hidrógeno o un grupo hidrocarburo sustituido en forma opcional; R³B, R³C, R⁴B y R⁴C son cada uno en forma independiente un átomo de hidrógeno o un sustituyente; cuando L¹ es CR³BR³C y el anillo Ar tiene sustituyente(s), R³B y el sustituyente se encuentran unidos en forma opcional entre sí para formar un anillo sustituido en forma opcional; X¹, X² y X³ son cada uno en forma independiente CR⁵ o N; R⁵ es un átomo de hidrógeno, un átomo de halógeno, un grupo ciano, un grupo alquilo C₁₋₆ sustituido en forma opcional, un grupo alcoxi C₁₋₆ sustituido en forma opcional o un grupo cicloalquilo C₃₋₁₀ sustituido en forma opcional; R¹ es un grupo alquilo C₁₋₆ sustituido en forma opcional o un grupo cíclico sustituido en forma opcional; R² es un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional o un grupo cíclico sustituido en forma opcional; Y¹, Y² e Y³ son cada uno en forma independiente CR⁶ o N; y R⁶ es un átomo de hidrógeno, un átomo de halógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional, un grupo alcoxi C₁₋₆ sustituido en forma opcional o un grupo cicloalquilo C₃₋₁₀ sustituido en forma opcional; o una sal del mismo.
ARP140102528A 2013-07-09 2014-07-08 Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch) AR096848A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013143940 2013-07-09

Publications (1)

Publication Number Publication Date
AR096848A1 true AR096848A1 (es) 2016-02-03

Family

ID=51220851

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102528A AR096848A1 (es) 2013-07-09 2014-07-08 Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)

Country Status (9)

Country Link
US (1) US9199963B2 (es)
EP (1) EP3019487A1 (es)
JP (1) JP2016523809A (es)
CN (1) CN105358544A (es)
AR (1) AR096848A1 (es)
CA (1) CA2917490A1 (es)
TW (1) TW201536767A (es)
UY (1) UY35650A (es)
WO (1) WO2015005489A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6129850B2 (ja) * 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体
US9440987B2 (en) * 2012-05-10 2016-09-13 Takeda Pharmaceutical Company Limited Aromatic ring compound
PE20221327A1 (es) 2019-12-20 2022-09-09 Bayer Ag Carboxamidas de tiofeno, acidos carboxilicos de tiofeno sustituidos y derivados de estos
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849708A (en) 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
EP0848060A3 (en) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Novel human 11CB splice variant
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
JP2001525178A (ja) 1997-12-03 2001-12-11 スミスクライン ビーチャム コーポレーション ヒト１１ｃｂスプライス変異体に対するアゴニストおよびアンタゴニストの探索方法
WO2000049170A1 (en) 1999-02-18 2000-08-24 Smithkline Beecham Corporation MURINE 11cby RECEPTOR
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU2001252596A1 (en) 2000-04-28 2001-11-12 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonists
AU2001269531A1 (en) 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
KR20040058191A (ko) 2001-10-01 2004-07-03 다이쇼 세이야꾸 가부시끼가이샤 Ｍｃｈ 수용체 안타고니스트
US7101845B2 (en) 2002-01-31 2006-09-05 Joslin Diabetes Center, Inc. Methods of modulating β cell function
OA12771A (en) 2002-02-14 2006-07-04 Pharmacia Corp Substituted pyridinones as modulators of P38 map kinase.
WO2004028453A2 (en) 2002-09-25 2004-04-08 Neurogen Corporation Methods for preventing and treating obesity in patients with mc4 receptor mutations
KR20050062645A (ko) 2002-11-01 2005-06-23 다케다 야쿠힌 고교 가부시키가이샤 신경병증의 예방 또는 치료제
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
NL1026826C2 (nl) 2003-08-13 2007-01-04 Pharmacia Corp Gesubstitueerde pyridinonen.
US7534887B2 (en) 2003-09-30 2009-05-19 Takeda Pharmaceutical Company Limited Thiazoline derivative and use of the same
WO2005040824A2 (en) 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
WO2005063729A1 (en) 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP1867341A4 (en) 2005-03-29 2009-07-29 Banyu Pharma Co Ltd THERAPEUTIC AGENT FOR NON-ALCOHOLIC HEPATIC ADPATIVE DISEASE, AND METHOD FOR SELECTING MEDICAMENTAL CANDIDATE COMPOUND FOR THE TREATMENT OR PREVENTION OF NON ALCOHOLIC HEPATIC ADAPTIVE DISEASE
JP5094394B2 (ja) 2005-04-20 2012-12-12 武田薬品工業株式会社 縮合複素環化合物
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
RU2008108984A (ru) 2005-08-10 2009-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) Терапевтический агент от диабета
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2621470A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
TWI354668B (en) 2006-06-27 2011-12-21 Takeda Pharmaceutical Fused cyclic compounds
EP2077267A4 (en) 2006-10-18 2010-04-07 Takeda Pharmaceutical FUSED HETEROCYCLIC COMPOUND
BRPI0717722A2 (pt) 2006-10-19 2013-10-29 Takeda Pharmaceutical Composto ou um sal do mesmo, pró-droga, ativador de glicoquinase, agente farmacêutico, métodos para ativar uma glicoquinase em um mamífero e para a profilaxia ou o tratamento de diabetes ou obesidade em um mamífero, e, uso do composto ou uma pró-droga do mesmo
WO2008070599A1 (en) 2006-12-05 2008-06-12 Chung-Ming Sun Indazole compounds
US8268868B2 (en) * 2007-01-10 2012-09-18 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
EP2125826A1 (en) 2007-01-10 2009-12-02 Albany Molecular Research, Inc. 5-furopyridinone substituted indazoles
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
BRPI0807014A2 (pt) 2007-02-09 2014-04-22 Takeda Pharmaceutical Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto.
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
US20110301155A1 (en) 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
WO2011127643A1 (en) 2010-04-12 2011-10-20 Merck Sharp & Dohme Corp. Pyridone derivatives
EP2558094A4 (en) 2010-04-12 2013-09-25 Merck Sharp & Dohme PYRIDONE DERIVATIVES
JP6129850B2 (ja) 2012-01-12 2017-05-17 武田薬品工業株式会社 Ｍｃｈ受容体拮抗剤としてのベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
US20150018373A1 (en) 2015-01-15
EP3019487A1 (en) 2016-05-18
JP2016523809A (ja) 2016-08-12
TW201536767A (zh) 2015-10-01
CA2917490A1 (en) 2015-01-15
CN105358544A (zh) 2016-02-24
WO2015005489A1 (en) 2015-01-15
UY35650A (es) 2015-02-27
US9199963B2 (en) 2015-12-01

Similar Documents

Publication Publication Date Title
AR118312A2 (es) Pesticidas de azol bicíclico sustituido con heterociclos
GT201700146A (es) Compuestos de triazolopirimidina y usos de los mismos
AR110038A1 (es) Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos
CR20160098A (es) Polimorfo de los inhibidores de la syk
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR097866A1 (es) Derivados de 4-azaindol
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
AR102977A1 (es) Inhibidores de erk
MX362582B (es) Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.
EA201692219A1 (ru) Способы получения противовирусных соединений
AR092270A1 (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR089527A1 (es) Inhibidores de bromodominios
PE20171511A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
AR111983A1 (es) ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR090836A1 (es) Derivados de benzamida
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR096848A1 (es) Derivados de indazol con actividad antagonista del receptor de la hormona concentradora de melanina (mch)
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR097963A1 (es) Antagonistas de receptor ep3 de prostaglandina
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре
AR097932A1 (es) Antagonista del receptor de somatostatina del subtipo 5 (sstr5)

Legal Events

Date Code Title Description
FB Suspension of granting procedure